3/21
07:10 am
vir
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Low
Report
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
3/21
07:10 am
vir
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
Low
Report
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results
3/13
08:05 am
vir
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
Medium
Report
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
3/1
07:07 pm
vir
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results [Yahoo! Finance]
Medium
Report
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results [Yahoo! Finance]
2/28
05:09 pm
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at Barclays PLC from $26.00 to $31.00. They now have an "overweight" rating on the stock.
Low
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at Barclays PLC from $26.00 to $31.00. They now have an "overweight" rating on the stock.
2/28
09:48 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
Medium
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
2/27
08:08 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
Medium
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
2/26
04:36 pm
vir
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
High
Report
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/26
04:05 pm
vir
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
High
Report
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
2/19
04:22 pm
vir
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference [Yahoo! Finance]
2/19
04:05 pm
vir
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
Low
Report
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
2/12
04:46 pm
vir
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 [Yahoo! Finance]
Medium
Report
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 [Yahoo! Finance]
2/12
04:05 pm
vir
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Medium
Report
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
2/4
07:50 am
vir
NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer [Yahoo! Finance]
Low
Report
NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer [Yahoo! Finance]
1/31
08:09 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
Low
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
1/13
11:41 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at Leerink Partners from $18.00 to $20.00. They now have an "outperform" rating on the stock.
Medium
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at Leerink Partners from $18.00 to $20.00. They now have an "outperform" rating on the stock.
1/10
08:04 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
Low
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
1/9
08:25 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at JPMorgan Chase & Co. from $10.00 to $14.00. They now have a "neutral" rating on the stock.
Medium
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at JPMorgan Chase & Co. from $10.00 to $14.00. They now have a "neutral" rating on the stock.
1/9
08:25 am
vir
Vir Biotechnology, Inc. (NASDAQ: VIR) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $10.00.
Medium
Report
Vir Biotechnology, Inc. (NASDAQ: VIR) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $10.00.
1/8
07:45 am
vir
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
High
Report
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC